What Quartette Treats: Main Uses and Benefits

Quartette, a combination oral contraceptive with an extended-cycle regimen, is commonly applied across therapeutic domains involving fertility control and the management of cyclical symptoms that interfere with daily functioning.

Reliable, Long-Term Pregnancy Prevention and Symptom Management

This medication is primarily relevant for females of reproductive potential seeking long-term pregnancy prevention, which is the fundamental indication for its use. This use supports the patient in maintaining autonomy regarding their family planning choices.

Beyond its primary function, the medication is considered relevant for easing symptoms related to physical discomfort that can become disruptive during menses. This includes the supportive management of symptom clusters such as severe menstrual pain (dysmenorrhea) and heavy menstrual bleeding (menorrhagia). The extended-cycle regimen is also commonly used to help with the easing of the frequency of scheduled withdrawal bleeding, a key benefit that generally results in approximately four periods per year.

The strategy of cycle modification is often preferred by patients. The extended-cycle format supports greater predictability and may assist in reducing time disrupted by monthly bleeding and its associated symptoms. By helping to ease the overall symptom load, the medication may assist with supporting functional stability during symptomatic periods.

---

Quick Fact: Relief for Cyclical Discomfort
Symptom Category	Benefit Provided
Severe Menstrual Pain	Supports easing of discomfort
Heavy Bleeding	Assists in addressing flow
Frequent Periods	Helps modify periodic manifestation

Eligibility Map: Who can and cannot use Quartette — Official Regulatory Information

---

Eligibility Scope

Classification	Population/Condition
Allowed	Females of reproductive potential (postpubertal).
Not Recommended	Females who are actively breastfeeding/lactating.
Contraindicated	Females over 35 years old who smoke.
Contraindicated	Current or history of thrombotic diseases (DVT, PE, stroke, or thrombophilias).
Contraindicated	Known or suspected pregnancy, breast cancer, or hormone-sensitive cancers.
Contraindicated	Active liver disease, liver tumors, or uncontrolled hypertension.

Age-Related Eligibility Rules

• Pediatric Use: Use is not indicated before menarche (start of periods).
• Geriatric Use: The product is not indicated for use in postmenopausal women.

Eligibility-Related Restrictions

• Postpartum Status: Use must be initiated no earlier than four weeks after delivery in non-breastfeeding women, due to an elevated risk of thromboembolism.
• Surgery: Must be stopped at least four weeks before and through two weeks after major surgery associated with thrombosis risk.
• Metabolic Conditions: An alternate contraceptive method should be considered for women with uncontrolled dyslipidemias.

Connection to the overall eligibility profile

Official regulatory documents define Quartette's eligibility profile by prohibiting its use in specific patient populations where the risk of serious cardiovascular or oncologic events is heightened. Eligibility is limited to postpubertal females who do not have any of the documented high-risk conditions, such as advanced age combined with smoking, a history of vascular disease, or active liver disease. Restricted use applies to the immediate postpartum period and times surrounding major surgery.

Quartette Interactions with other medicines and products

Interactions with Quartette, a combination oral contraceptive, are based on how other substances affect the metabolism of its active ingredients, Levonorgestrel and Ethinyl Estradiol, and how the contraceptive itself affects other drugs.

---

Contraindicated Drug Combinations

Co-administration is formally contraindicated with specific Hepatitis C drug regimens. This prohibition applies to medicinal products containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, or regimens containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprivir due to the documented risk of liver enzyme (ALT) elevations.

---

Official Pharmacokinetic Interactions

Interaction Type	Interacting Substance Examples	Regulatory Outcome Statement
Enzyme Induction	Carbamazepine, Rifampicin, St. John's wort	Increases the hormones' clearance via CYP3A4 induction, leading to decreased plasma concentrations and reduced efficacy.
Enzyme Inhibition	Itraconazole, Erythromycin, Fluconazole	May increase the plasma concentrations of the hormones, potentially increasing the risk of adverse effects.
Interference (on other drugs)	Lamotrigine, Cyclosporine, Tizanidine	May cause decreased plasma levels of Lamotrigine and increased plasma levels of drugs like Cyclosporine and Tizanidine.
Exposure Modifiers	Etoricoxib, Sugammadex	Etoricoxib increases Ethinyl Estradiol exposure (up to 1.6-fold); Sugammadex is predicted to cause a decrease in progestogen exposure.

---

Interaction-Related Constraints

• Timing Rule: A non-hormonal barrier method is required during co-administration with enzyme-inducing drugs and for 28 days after their discontinuation.
• Restart Rule: Following treatment with the contraindicated Hepatitis C regimens, Quartette can be restarted 2 weeks following completion of the antiviral therapy.

Quartette is a combination preparation containing the progestin levonorgestrel and the estrogen ethinyl estradiol.

Biological Targets and Pathways

Its pharmacodynamic action involves modulation of the hypothalamic-pituitary-ovarian (HPO) axis.

• Levonorgestrel acts as a progesterone receptor agonist, binding to intracellular progesterone receptors in target tissues, including the hypothalamus and pituitary gland. This interaction suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and, consequently, the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary.
• The ethinyl estradiol component is an estrogen receptor agonist that potentiates the HPO axis suppression by stabilizing pituitary FSH and LH levels at a low range, reinforcing the negative feedback loop.

Intracellular and System-Level Consequences

The resulting systemic suppression of gonadotropins prevents the mid-cycle LH surge, which is the molecular signal for ovulation. Additional modulation occurs at the cervix and endometrium. Progestin activity thickens cervical mucus, creating a biophysical barrier to sperm transit, and induces endometrial morphological changes (e.g., stromal pseudodecidualization and glandular atrophy), altering the inner lining of the uterus.

How to Use Quartette

The administration of Quartette is defined by a fixed, sequential, 91-day extended-cycle regimen that dictates the precise pattern of oral tablet intake. The medication is administered orally, with one film-coated tablet taken once daily for 91 consecutive days. Maintaining a consistent 24-hour interval between doses is essential, meaning the tablet should be consumed at the same time every day.

The quadriphasic nature of the drug requires strict adherence to the sequential order printed on the blister pack, as the concentrations of Levonorgestrel and Ethinyl Estradiol change four times across the cycle. For instance, the highest combination strength is 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol, which is taken during the third phase of the course. The course is structured so that scheduled withdrawal bleeding typically occurs during the final 7 days of low-dose estrogen-only tablets.

Initiation of the first course typically begins on the first Sunday after the start of a menstrual period, and a non-hormonal back-up method is required for the initial seven days of treatment. Furthermore, specific timing constraints apply to initiation, specifying that the course should not be started until four weeks after a second-trimester abortion or delivery. Following the completion of the 91-day course, the subsequent course is commenced without any tablet-free break, continuing the long-term extended-cycle pattern. Instructions for handling missed doses are complex and depend critically on both the number of tablets missed and the hormone phase of the cycle.

Research Evidence / Overview of Studies for Quartette

Evidence for Use in Pregnancy Prevention (Contraception)

The primary evidence for this medication was evaluated in large-scale, multicenter clinical trials conducted for regulatory assessment. These studies was studied for outcomes related to systemic or functional imbalance, focusing on pregnancy rates in sexually active females of reproductive age. Researchers monitored these outcomes using measures like the Pearl Index. Findings from the trials describe patterns observed in the studies regarding measured pregnancy rates. Subgroup analysis, such as that based on body weight, data show patterns related to minor variations in measured outcomes. The key point is that research provides context but not individual predictions, as measured outcomes in the trials may differ from those observed under real-world typical use conditions.

---

Evidence for Managing Bleeding Patterns and Cyclical Discomfort

The extended-cycle regimen was evaluated in research exploring short-term symptom changes through Randomized Controlled Trials (RCTs). Research explored outcomes related to physical discomfort by tracking total bleeding and spotting days and specifically monitoring the change in the frequency of scheduled withdrawal bleeding. Studies report how symptoms evolved in the observed populations regarding bleeding frequency, although findings were mixed regarding how the pattern of unscheduled bleeding may influence adherence. Evidence provides insight into short-term changes in these bleeding patterns over the course of the first year of use.

---

Evidence Gaps and Areas of Scientific Uncertainty

Scientific consensus highlights several areas where certainty remains low. Follow-up durations were limited in the primary regulatory studies, meaning that long-term effects are not fully established beyond approximately one year of use. Furthermore, data for certain groups remain insufficient, particularly for patients with specific comorbid conditions, meaning that results apply only to the populations studied. The research does not determine whether an individual will respond similarly to the group patterns observed in trials, and comparative evidence is lacking when research examined different extended-cycle combination contraceptives.

Common questions about Quartette (FAQ)

---

Q: Does Quartette have an alternative name or generic version?

The active ingredients in Quartette are levonorgestrel and ethinyl estradiol, which are available in many generic forms of combined oral contraceptives. The name Quartette refers specifically to its unique quadriphasic, extended-cycle formulation. The availability of a generic version of the extended-cycle regimen can be confirmed by a healthcare provider or pharmacist.

---

Q: Is Quartette used for conditions other than the primary one mentioned in the label?

Official labeling states that the primary indication for Quartette is the prevention of pregnancy. The extended-cycle regimen is designed to reduce the frequency of scheduled withdrawal bleeding to approximately four times per year.

---

Q: How quickly can a person expect to notice the effects of Quartette?

According to the official product information, when starting this medication, a non-hormonal back-up method of contraception is advised for the first seven days of use. This requirement is described in the official label regarding the onset of contraceptive efficacy.

---

Q: What is the typical duration of treatment with Quartette?

Quartette is designed for a continuous extended-cycle regimen of 91 days per course, which is then started again without interruption. The decision to continue or stop the extended-cycle regimen is determined in consultation with a healthcare provider.

---

Q: Is it common to feel tired after starting Quartette?

While fatigue is not listed among the most common side effects (Very Common or Common) reported in the initial clinical trials, it has been reported in association with this drug class during post-approval use. The medication’s safety documentation notes that the most frequently reported side effects in clinical trials include headache and nausea.

---

Q: Can taking Quartette cause weight gain or loss?

Official regulatory documents list increased weight as one of the common adverse reactions reported by patients during clinical studies. Individual experiences may vary. Any significant change in body weight is a matter to be addressed with a healthcare provider.

---

Q: Are the side effects of Quartette usually temporary or do they last a long time?

The most common side effect experienced by users is irregular bleeding or spotting. Official documentation notes that this type of bleeding tends to decrease over the course of the first few 91-day cycles as the body adjusts to the extended-cycle regimen.

---

Q: What are the most serious side effects of Quartette that people talk about online?

The most clinically significant safety concern documented in regulatory labeling is the risk of Thromboembolism. This includes serious conditions like Deep Vein Thrombosis (DVT), Pulmonary Embolism, Stroke, and Myocardial Infarction.

---

Q: Can drinking alcohol while taking Quartette cause problems?

Drug interaction checkers classify the combination of alcohol (ethanol) with the active ingredients as a minor interaction. A healthcare provider can offer personalized guidance regarding the consumption of alcohol while using this medication.

---

Q: Is it possible for Quartette to interact with herbal supplements?

Yes, official prescribing information explicitly warns that products containing the herbal supplement St. John's wort may significantly decrease the effectiveness of the hormones in Quartette. The interaction can decrease the effectiveness of the hormones in Quartette.

---

Q: Are there any specific foods or drinks to avoid when taking Quartette?

Regulatory information advises that consuming grapefruit or grapefruit juice may lead to increased plasma levels of the estrogen component. This may lead to increased plasma levels of the estrogen component, which is associated with a risk of certain side effects.

---

Q: What does the official patient information say about stopping Quartette?

Official labeling provides clear instructions for discontinuing the medication in specific medical circumstances. These include if a pregnancy occurs, before and after major surgery that carries a risk of thrombosis, or if experiencing a serious thrombotic event.

---

Q: Do children or elderly people need a special evaluation before using Quartette?

The product is not indicated for use before menarche (the start of periods) or after menopause. Official warnings emphasize that a patient's cardiovascular risk factors should be carefully considered before beginning treatment, especially for females over 35 years old.

---

Q: Are there any long-term research findings about using Quartette?

The primary regulatory clinical studies used to evaluate this medication typically included follow-up durations of approximately one year. Therefore, long-term effects beyond this one-year period are generally not fully established in the primary product documentation.

---

Q: How does Quartette affect common laboratory blood tests?

Regulatory documents contain a dedicated section detailing how hormonal contraceptives may influence the results of certain laboratory blood tests. These potential changes often relate to hormone-binding globulins, blood clotting factors, and lipid levels.

---

Q: Is it normal to have mild headaches when first taking Quartette?

Headache is classified as a very common adverse reaction based on findings from clinical studies. The official label notes that a significant change in the pattern of headaches may warrant evaluation by a healthcare provider.

How to Store and Dispose of Quartette

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) must be stored and disposed of according to the specific conditions defined in official regulatory labeling to maintain stability and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.
Container	Keep the tablets in the original packaging (Extended-Cycle Tablet Dispenser) until the time of use.
Child Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

For disposal of unused or expired Quartette, the preferred method is to use a drug take-back program or mail-back envelope. If these options are unavailable, the medicine can be disposed of in household trash only after being mixed with an undesirable substance (e.g., dirt, used coffee grounds) and sealed in a bag or container. The medication must not be flushed down a toilet or poured down a sink.